arrow
W

Walter M. Stadler

the university of chicago medical center
H指数:95
被引数:4.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

11 Long-Term Follow-Up from the OMNIVORE Trial: Response-Adaptive Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma (NCT03652142)

11 OMNIVORE试验的长期随访:适应性纳武利尤单抗和伊匹木单抗在晚期肾细胞癌中的疗效(NCT03652142)

2026-09-020
OAAI
66 Relationship Between Health-related Quality of Life and Efficacy in the Phase 3 LITESPARK-005 Study of Belzutifan versus Everolimus in Previously Treated Advanced Clear Cell Renal Cell Carcinoma

66 健康相关生活质量与疗效在LITESPARK-005研究(比较Belzutifan与Everolimus在先前治疗过的晚期透明细胞肾细胞癌中的效果)第三阶段的关系

2026-09-020
OAAI
Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)

III期LITESPARK-005研究最终分析:比较belzutifan与everolimus在先前接受过治疗的晚期透明细胞肾细胞癌(ccRCC)患者(pts)中的效果

2024-09-012
PRE
Feasibility of structuring electronic health record data to facilitate real-world data research: ICAREdata methods applied to multicenter cancer clinical trials

构建电子健康记录数据以促进真实世界数据研究的可行性: ICAREdata方法应用于多中心癌症临床试验

CANCER
IF5.1
2024-08-282
OAAI
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
2024-08-225
PRE
Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study
2023-10-0129
PRE
Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics
2023-08-135
OAAI
Genetic factors associated with prostate cancer conversion from active surveillance to treatment
2022-01-0121
OAAI
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial
2021-05-0124
OAAI
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)
CANCER
IF5.1
2021-03-2542
OAAI
Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer

乳腺癌和前列腺癌患者化疗前、期间和化疗后药物 (包括草药和补充剂) 潜在相互作用的患病率

CANCER
IF5.1
2021-02-0128
OAAI